Key factors influencing dose selection include: Treatment goals : Whether the primary aim is glycaemic control, weight reduction, or cardiovascular risk reduction Baseline HbA1c and blood glucose levels : Higher values may eventually require higher maintenance doses Body weight and BMI : Particularly relevant for weight management indications Renal function : Most GLP-1 medications (semaglutide, liraglutide, dulaglutide) do not require dose adjustment for kidney impairment, but exenatide and lixisenatide should be used with caution or avoided in severe renal impairment Concurrent medications : Especially other glucose-lowering agents that might increase hypoglycaemia risk Previous medication tolerance : History of gastrointestinal sensitivity influences titration speed Cardiovascular history : Some GLP-1 medications have proven cardiovascular benefits at specific doses Diabetic retinopathy status : Rapid improvement in blood glucose can temporarily worsen retinopathy, particularly with semaglutide [22] [23] Your doctor will typically schedule regular follow-up appointments during the initial months of treatment
TRN, tegmental reticular nucleus
Who Should Be Cautious
All this translates into an improvement in glycemic control and dyslipidemia, a reduction in blood pressure, weight, and ectopic visceral fat deposits, as well as inflammation and coagulation, which could translate into greater cardiovasculorenal protection with the use of these drugs
Food noise or hunger has returned: A sign that a dose is no longer sufficient is the return of intrusive thoughts about food or a noticeable decrease in feelings of fullness after meals
How Orforglipron Performed in People With Type 2 Diabetes Participants with diabetes saw two main benefits: Improved blood sugar control , including HbA1c reductions of up to 1.6%
